12 Month Price Forecast For ESLA
Distance to ESLA Price Forecasts
ESLA Price Momentum
๐ค Considering Estrella Immunopharma (ESLA)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 10:57 AM UTC
ESLA Analyst Ratings & Price Targets
Currently, there are no Wall Street analyst price targets or forecasts available for ESLA (Estrella Immunopharma).
ESLA is currently trading at $1.12. Without active analyst coverage, investors should conduct thorough independent research and consider multiple data points beyond price targets when evaluating this stock for their portfolio.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ESLA Analyst Consensus
ESLA Price Target Range
Latest ESLA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ESLA.
Date | Firm | Analyst | Rating | Change | Price Target |
---|
Stocks Similar to Estrella Immunopharma Inc
The following stocks are similar to Estrella Immunopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Estrella Immunopharma Inc (ESLA) Financial Data
Estrella Immunopharma Inc has a market capitalization of $40.52M with a P/E ratio of -4.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -171.1%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Estrella Immunopharma Inc (ESLA) Company Overview
About Estrella Immunopharma Inc
Develops T-cell therapies for cancers.
Estrella Immunopharma focuses on developing innovative T-cell therapies targeting blood cancers and solid tumors. The company generates revenue through collaborations, clinical trials, and potential future product sales based on its promising pipeline of therapeutic candidates.
Founded in 2006 and headquartered in Emeryville, California, the company is currently advancing its lead product candidates through clinical and pre-clinical trials. It has established a partnership with Imugene Limited to enhance the development of treatments for solid tumors.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Dr. Cheng Liu Ph.D.
Country
United States
IPO Year
2021
Website
www.estrellabio.comEstrella Immunopharma Inc (ESLA) Latest News & Analysis
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMISยฎ T-cells
4 months agoEstrella Immunopharma announced that the first patient in its STARLIGHT-1 Phase I/II trial achieved a complete response after receiving EB103 CD19-Redirected ARTEMISยฎ T Cells.
The successful enrollment and complete response in Estrella's clinical trial can boost investor confidence, potentially leading to increased stock value and interest in the company's therapies.
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
5 months agoEstrella Immunopharma appointed Hong Zhang as Chairperson and Board member. This follows the first patient dosing in its Phase I/II clinical trial for CD19 and CD22-targeted therapies.
The appointment of a new Chairperson and progress in clinical trials can signal strategic shifts and potential advancements in product development, influencing investor sentiment and stock performance.
The IMF states most effects of tighter monetary policies on the U.S. economy have occurred, with remaining impacts expected this year. The U.S. has demonstrated resilience and growth since March 2022.
The IMF's assessment indicates potential stability in the U.S. economy, suggesting less risk of recession and encouraging investor confidence amid tighter monetary policies.
Frequently Asked Questions About ESLA Stock
What is Estrella Immunopharma Inc's (ESLA) stock forecast for 2025?
Analyst forecasts for Estrella Immunopharma Inc (ESLA) are not currently available. The stock is trading at $1.12.
Is ESLA stock a good investment in 2025?
Analyst ratings for ESLA are not currently available. The stock is currently trading at $1.12. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ESLA stock?
Price predictions from Wall Street analysts for ESLA are not currently available. The stock is trading at $1.12.
What is Estrella Immunopharma Inc's business model?
Estrella Immunopharma focuses on developing innovative T-cell therapies targeting blood cancers and solid tumors. The company generates revenue through collaborations, clinical trials, and potential future product sales based on its promising pipeline of therapeutic candidates.
What is the highest forecasted price for ESLA Estrella Immunopharma Inc?
Price targets from Wall Street analysts for ESLA are not currently available. The stock is trading at $1.12.
What is the lowest forecasted price for ESLA Estrella Immunopharma Inc?
Price targets from Wall Street analysts for ESLA are not currently available. The stock is trading at $1.12.
What is the overall ESLA consensus from analysts for Estrella Immunopharma Inc?
Analyst ratings for ESLA are not currently available. The stock is trading at $1.12.
How accurate are ESLA stock price projections?
Stock price projections, including those for Estrella Immunopharma Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.